速递｜替尔泊肽卖爆，2024年药企薪酬礼来CEO跃居榜首

GLP1减重宝典2025-05-03

整理 | GLP1减重宝典内容团队礼来公司首席执行官大卫·里克斯 (David Ricks) 超越强生公司首席执行官华金·杜阿托 (Joaquin Duato)，成为制药行业薪酬最高的首席执行官，2024 年他的薪酬为 2920 万美元。里克斯和他的团队经历了风风火火的一年，清理了积压的生产和供应订单，正式将减肥药 Zepbound 推向了畅销市场，这也就不足为奇了。里克斯的薪酬比 2023 年...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2532381235?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-03 13:27","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2532381235","market":"us","top_or_hot":-1,"title":"速递｜替尔泊肽卖爆，2024年药企薪酬礼来CEO跃居榜首","media":"GLP1减重宝典","content":"<div>\n<p>整理 | GLP1减重宝典内容团队礼来公司首席执行官大卫·里克斯 (David Ricks) 超越强生公司首席执行官华金·杜阿托 (Joaquin Duato)，成为制药行业薪酬最高的首席执行官，2024 年他的薪酬为 2920 万美元。里克斯和他的团队经历了风风火火的一年，清理了积压的生产和供应订单，正式将减肥药 Zepbound 推向了畅销市场，这也就不足为奇了。里克斯的薪酬比 2023 年...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503150513a470b7c6&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>速递｜替尔泊肽卖爆，2024年药企薪酬礼来CEO跃居榜首</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n速递｜替尔泊肽卖爆，2024年药企薪酬礼来CEO跃居榜首\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-03 13:27 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503150513a470b7c6&s=b><strong>GLP1减重宝典</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>整理 | GLP1减重宝典内容团队礼来公司首席执行官大卫·里克斯 (David Ricks) 超越强生公司首席执行官华金·杜阿托 (Joaquin Duato)，成为制药行业薪酬最高的首席执行官，2024 年他的薪酬为 2920 万美元。里克斯和他的团队经历了风风火火的一年，清理了积压的生产和供应订单，正式将减肥药 Zepbound 推向了畅销市场，这也就不足为奇了。里克斯的薪酬比 2023 年...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503150513a470b7c6&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237443622.USD","symbol_name":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503150513a470b7c6&s=b","article_id":"2532381235","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250503150513a470b7c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2532381235","pubTimestamp":1746250034,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"里克斯的薪酬比 2023 年增长了 10%。相反，杜阿托在 2024 年的薪酬下降了约 14%，以略低于 2460 万美元的薪酬位列第三。从各方面来看，礼来公司2024年的表现都相当不错。根据礼来公司年报，在里克斯的带领下，公司2024年的收入增长了32%，达到450亿美元，非公认会计准则每股收益增长了106%，达到12.99美元。报道称，所有这些都帮助自 2017 年起担任礼来公司首席执行官的里克斯获得了超出目标的薪酬。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU2361044949.HKD":"WELLINGTON US QUALITY GROWTH \"A\" (HKD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4581":"高盛持仓","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2361045086.USD":"WELLINGTON US QUALITY GROWTH \"A\" (USD) ACC","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU2750360641.GBP":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (GBPHDG) INC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LLY":"礼来","BK4588":"碎股","LU0203202063.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A2X\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999001176.USD":"United Global Healthcare Acc USD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","BK4516":"特朗普概念"},"translate_title":"Express | Tilpotide is selling out, and the CEO of pharmaceutical companies will jump to the top of the list in 2024","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"整理 | GLP1减重宝典内容团队礼来公司首席执行官大卫·里克斯 (David Ricks) 超越强生公司首席执行官华金·杜阿托 (Joaquin Duato)，成为制药行业薪酬最高的首席执行官，2024 年他的薪酬为 2920 万美元。里克斯和他的团队经历了风风火火的一年，清理了积压的生产和供应订单，正式将减肥药 Zepbound 推向了畅销市场，这也就不足为奇了。里克斯的薪酬比 2023 年增长了 10%。辉瑞公司的阿尔伯特·布尔拉 (Albert Bourla) 的薪酬也大幅上涨，增长了 14%，2024 年的薪酬略高于 2460 万美元。相反，杜阿托在 2024 年的薪酬下降了约 14%，以略低于 2460 万美元的薪酬位列第三。从上往下依次为：安进公司的罗伯特·布拉德韦 (Robert Bradway)、吉利德公司的丹尼尔·奥戴 (Daniel O’Day) 和默克公司的罗伯特·戴维斯 (Robert Davis)，分别位列第四、第五和第六，年薪均超过 2300 万美元。高管们的大部分收入来自股票期权，这也是Ricks获得巨额薪酬的方式，高达1970万美元。罗氏公司的Thomas Schinecker的基本工资最高，为370万美元。该行业的奖金很少，尤其是在美国公司，这些公司今年没有公布任何高管奖金。股票和其他激励措施往往会起到提振作用。在我们榜单上提供奖金的公司中，Schinecker的奖金最高，为390万美元。从各方面来看，礼来公司2024年的表现都相当不错。根据礼来公司年报，在里克斯的带领下，公司2024年的收入增长了32%，达到450亿美元，非公认会计准则每股收益增长了106%，达到12.99美元。在里克斯的领导下，阿尔茨海默病单克隆抗体Kisunla最终获得批准，而用于治疗克罗恩病的Ebglyss也获得了FDA的批准。公司还公布了多项积极的数据，包括多项关于tirzepatide在降低心力衰竭和糖尿病风险方面的研究。在交易方面，里克斯主导了对免疫生物技术公司Morphic Holdings的收购。他还负责监督新研发设施和生产基地的开发，并推出了LillyDirect，这是一个直接面向消费者的门户网站，方便用户获取礼来公司的药品，例如减肥药Zepbound。报道称，所有这些都帮助自 2017 年起担任礼来公司首席执行官的里克斯获得了超出目标的薪酬。*本文仅供医疗卫生专业人士参考","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2532381235","isCrawlerRequest":true}